BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2021

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	December 31,		December 31,
	2021		2020
Research and development services (over-time)	$	105,695	$	263,713
Clinical laboratory testing services (point-in-time)		1,873,722		578,370
Clinical laboratory testing services (over-time)		1,326,400		194,400
Product and authentication services (point-in-time):
Supply chain		411,547		32,942
Asset marking		105,522		151,758
Diagnostic test kits		342,820		394,958
Total	$	4,165,706	$	1,616,141

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		December 31,		$
	Balance sheet classification	2021		2021		change
Contract liabilities	Deferred revenue	$	281,000	$	457,538	$	176,538

Schedule of anti-dilutive securities not included computation of net loss per share

	2021	2020
Warrants	743,563	778,118
Stock options	1,061,460	358,178
Total	1,805,023	1,136,296